Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients
- Conditions
- Respiratory Syncytial Virus Infections
- Registration Number
- NCT00031473
- Brief Summary
The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.
- Detailed Description
The study enrolls 90 transplant recipients with positive nasal/throat culture specimens for Respiratory Syncytial Virus (RSV) infection. Patients are randomized into one of two groups: investigational treatment or standard treatment.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 90
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
University of Alabama at Birmingham (CASG)
🇺🇸Birmingham, Alabama, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
J. Whitcomb Riley Hosp for Chldrn - Indianapolis
🇺🇸Indianapolis, Indiana, United States
University of Maryland
🇺🇸Baltimore, Maryland, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
University of Florida
🇺🇸Gainesville, Florida, United States
St. Luke's Hospital (Kansas City, MO)
🇺🇸Kansas City, Missouri, United States